Cited by 371Rheumatoid Arthritis Research and TherapiesInfluenza Virus Research StudiesVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

van Assen, Sander, Holvast, Albert, Benne, Cornelis A., Posthumus, Marcel D., van Leeuwen, Miek A., Voskuyl, Alexandre E., Blom, Marlies, Risselada, Anke P., de Haan, Aalzen, Westra, Johanna, Kallenberg, Cees G. M., Bijl, Marc·2010·Arthritis & Rheumatism

DOI 10.1002/art.25033

Open this paper in CoChat — free account

Abstract

Objective: For patients with rheumatoid arthritis (RA), yearly influenza vaccination is recommended. However, its efficacy in patients treated with rituximab is unknown. The objectives of this study were to investigate the efficacy of influenza vaccination in RA patients treated with rituximab and to investigate the duration of the possible suppression of the humoral immune response following rituximab treatment. We also undertook to assess the safety of influenza vaccination and the effects of previous influenza vaccination. Methods: Trivalent influenza subunit vaccine was administered to 23 RA patients who had received rituximab (4–8 weeks after rituximab for 11 patients [the early rituximab subgroup] and 6–10 months after rituximab for 12 patients [the late rituximab subgroup]), 20 RA patients receiving methotrexate (MTX), and 29 healthy controls. Levels of antibodies against the 3 vaccine strains were measured before and 28 days after vaccination using hemagglutination inhibition assay. The Disease Activity Score in 28 joints (DAS28) was used to assess RA activity. Results: Following vaccination, geometric mean titers (GMTs) of antiinfluenza antibodies significantly increased for all influenza strains in the MTX‐treated group and in healthy controls, but for no strains in the rituximab‐treated group. However, in the late rituximab subgroup, a rise in GMT for the A/H3N2 and A/H1N1 strains was demonstrated, in the absence of a repopulation of CD19+ cells at the time of vaccination. Seroconversion and seroprotection occurred less often in the rituximab‐treated group than in the MTX‐treated group for the A/H3N2 and A/H1N1 strains, while seroprotection occurred less often in the rituximab‐treated group than in the healthy controls for the A/H1N1 strain. Compared with unvaccinated patients in the rituximab‐treated group, previously vaccinated patients in the rituximab‐treated group had higher pre‐ and postvaccination GMTs for the A/H1N1 strain. The DAS28 did not change after vaccination. Conclusion: Rituximab reduces humoral responses following influenza vaccination in RA patients, with a modestly restored response 6–10 months after rituximab administration. Previous influenza vaccination in rituximab‐treated patients increases pre‐ and postvaccination titers. RA activity was not influenced.

Integrity signals

Registry

Crossref · 10.1002/art.25033

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,753
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,742
Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,325
Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
(1997) · PsycEXTRA Dataset · doi:10.1037/e547512006-001 · Cited by 999
T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly
McElhaney, J. E., Xie, D., Hager, W. D., Barry, M. B., Wang, Y., Kleppinger, A., Ewen, C., Kane, K. P., & Bleackley, R. C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.6333 · Cited by 561
Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritis
Roll, P., Palanichamy, A., Kneitz, C., Dörner, T., & Tony, H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22019 · Cited by 321
Haemagglutination-inhibiting antibody to influenza virus.
de Jong, J. C., Palache, A. M., BEYER, W. E. P., Rimmelzwaan, G. F., Boon, A. C. M., & Osterhaus, A. D. M. E. (2003) · PubMed · Cited by 319
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers
Фомин, И. Н., Caspi, D., Levy, V., Varsano, N., Shalev, Y., Paran, D., Levartovsky, D., Litinsky, I., Kaufman, I., Wigler, I., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.036434 · Cited by 266
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response
Oren, S., Mandelboim, M., Braun‐Moscovici, Y., Paran, D., Ablin, J. N., Litinsky, I., Comaneshter, D. S., Levartovsky, D., Mendelson, E., Azar, R., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.077461 · Cited by 242

Flagged first, then by citations

Show all 18 references

Sorted by citations

Items 201–300 of 371

A literature review on the patients with autoimmune diseases following vaccination against infections
Liang, Y., Meng, F., Pan, H., & Ye, D. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1009337 · Cited by 13
The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab
Mustafa, S. S., Jamshed, S., Vadamalai, K., & Ramsey, A. C. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.006 · Cited by 13
COVID-19 vaccine failure in a patient on rituximab therapy
Chilimuri, S. S., Mantri, N., Zahid, M., & Sun, H. (2021) · Rheumatology Advances in Practice · doi:10.1093/rap/rkab038 · Cited by 12
Consensus Based Indian Guidelines for the Management of Pemphigus Vulgaris and Pemphigus Foliaceous
De, D., Mehta, H., Shah, S., Ajithkumar, K., Barua, S., Chandrashekar, L., Chatterjee, M., Gupta, V., Khandpur, S., Khullar, G., et al. (2024) · Indian Dermatology Online Journal · doi:10.4103/idoj.idoj_1059_24 · Cited by 11
Vaccination Recommendations for Adults With Autoimmune Inflammatory Rheumatic Diseases in Latin America
Brenol, C. V., Azevedo, V. F., Bonvehí, P., Coral-Alvarado, P. X., Granados, J., Muñoz-Louis, R., Pineda, C., & Vizzotti, C. (2017) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000624 · Cited by 12
“, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], systemic sclerosis, spondyloarthritis).(1,2) The heightened risk of infections in these patients is due to the nature of the diseases themselves, as well as the various immunomodulatory medications routinely prescribed.”
Background
Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
Dave, N., Gopalakrishnan, S., Mensing, S., & Salem, A. H. (2019) · Clinical and Translational Science · doi:10.1111/cts.12665 · Cited by 11
Empfehlungen zum Einsatz von Rituximab bei Patienten mit rheumatoider Arthritis
der DGRh, K. P., Rubbert‐Roth, A., Burmester, G. R., Dörner, T., & Gause, A. (2014) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-013-1238-2 · Cited by 11
Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis
Kogure, T., Harada, N., Tatsumi, T., & Fujinaga, H. (2014) · Clinical Rheumatology · doi:10.1007/s10067-013-2483-0 · Cited by 11
Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases
Guerrini, G., Franzetti, F., Giacomelli, R., Meroni, L., Riva, A., Scirè, C. A., Scrivo, R., Tavio, M., Agostinone, A., Airó, P., et al. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/hj69ne · Cited by 10
Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine
Tedeschi, S. K., Solomon, D. H., Chen, Y., Ellrodt, J., Whelan, M. G., Stratton, J., Hayashi, K., Whiteman, N. B., Chen, L., Adejoorin, I., et al. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152177 · Cited by 9
“response to COVID-19 vaccination [10-12] and reduced antibody production following influenza vaccination [13-15].”
Influential
COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes
Kahlmann, V., Manansala, M., Moor, C. C., Shahrara, S., Wijsenbeek, M. S., & Sweiss, N. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000812 · Cited by 10
“Conversely, RA patients on B-cell depleting therapy demonstrate a decreased antibody response to influenza vaccination [58–60], although this effect may be mitigated by administering the vaccine at least 6months after the last dose of therapy [60,61].”
Background
Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study
Terada, M., Kondo, N., Wanifuchi‐Endo, Y., Fujita, T., Asano, T., Hisada, T., Uemoto, Y., Kato, A., Yamanaka, N., Sugiura, H., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06693-2 · Cited by 11
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response
Ozog, S., Krantz, E. M., Tindbaek, K., Munoz, J., Liu, W. L., Chalal, C., Pernikoff, S., Yahya, K., Stevens‐Ayers, T., Dasgupta, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71473-1 · Cited by 9
Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities
Zand, L., Specks, U., Sethi, S. M., & Fervenza, F. C. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.01.009 · Cited by 9
“These studies suggest that treatment with rituximab lowers the immune response to pneumococcal (a T-cellindependent antigen) and influenza vaccination, but it has no effect on tetanus toxoid vaccine (T-cell-dependent antigen).(73,74) Therefore, it is recommended that patients receive nonlive vaccines 4 weeks before re…”
Background
Infektionskomplikationen unter Biologika-Therapie bei Patienten mit rheumatoider Arthritis
Meyer‐Olson, D., Hoeper, K., & Schmidt, R. E. (2010) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-010-0677-2 · Cited by 9
Vacunas y quimioprofilaxis en artritis reumatoide: ¿podría plantearse un calendario de vacunación?
López, B. C. G., Compán, M. V. N., & Sarabia, F. N. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.01.005 · Cited by 9
Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review
Rivera‐Izquierdo, M., Valero-Ubierna, M. D. C., Nieto-Gómez, P., Martínez-Bellón, M. D., Fernández‐Martínez, N. F., & Quintana, J. L. B. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1800462 · Cited by 10
Potential ‘significance’ of monoclonal gammopathy of ‘undetermined significance’ during COVID-19 pandemic
Jain, A., & Ramasamy, K. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102481 · Cited by 9
Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination
Gumber, L., Gomez, N. E., Hopkins, G. V., Tucis, D., Bartlett, L. G., Ayling, K., Vedhara, K., Steers, G., Chakravorty, M., Rutter, M., et al. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac574 · Cited by 9
PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
Humphrey, T. J. L., Dosanjh, D. P. S., Hiemstra, T. F., Richter, A. G., Chen-Xu, M., Qian, W., Jha, V., Gatley, K., Adhikari, R., Dowling, F., et al. (2023) · Trials · doi:10.1186/s13063-023-07128-z · Cited by 9
Consenso de uso de rituximab en artritis reumatoide. Un documento con recomendaciones basadas en la evidencia
Mola, E. M., Hernández‐Cruz, B., García‐Arias, M., Álvaro‐Gracia, J. M., Balsa, A., Gómez-Reino, J. J., de la Fuente, J. L. M., Martínez-Taboada, V. M., Ivorra, J. A. R., & Sanmartí, R. (2010) · Reumatología Clínica · doi:10.1016/j.reuma.2010.11.002 · Cited by 9
Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV‑2/COVID‑19-Pandemie einschließlich Empfehlungen zur COVID‑19-Impfung
Specker, C., Aries, P. M., Braun, J., Burmester, G. R., Fischer‐Betz, R., Hasseli, R., Holle, J. U., Hoyer, B. F., Iking‐Konert, C., Krause, A., et al. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01056-6 · Cited by 9
Management of vaccination in rheumatic disease
Wong, P. K. K., & Hanrahan, P. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.03.006 · Cited by 8
Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis
Scarpato, S., Sebastiani, M., Quartuccio, L., Marson, P., Fraticelli, P., Castelnovo, L., Visentini, M., Candela, M., Mazzaro, C., Saccardo, F., et al. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/2v6v5j · Cited by 8
Impfungen in der Rheumatologie
Feuchtenberger, M., Voll, R. E., & Kneitz, C. (2010) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-010-0707-0 · Cited by 8
SARS-COV-2 vaccine responses in renal patient populations
Smith, R., Cooper, D. J., Döffinger, R., Stacey, H., Al-Mohammad, A., Goodfellow, I., Baker, S. G., Lear, S. E., Hosmillo, M. D. T., Pritchard, N., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02792-w · Cited by 8
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients – Lessons learned from the COVID-19 pandemic
Wroński, J., Ciechomska, M., & Kuca‐Warnawin, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115254 · Cited by 5
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
Galota, F., Marcheselli, S., Biasi, S. D., Gibellini, L., Vitetta, F., Fiore, A., Smolik, K., Napoli, G. D., Cardi, M., Cossarizza, A., et al. (2025) · Cells · doi:10.3390/cells14080606 · Cited by 7
Vaccines and Chemo-prophylaxis in Rheumatoid Arthritis: Is a Vaccine Calendar Necessary?
López, B. C. G., Compán, M. V. N., & Sarabia, F. N. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.01.004 · Cited by 7
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond
Beecker, J. R., Papp, K. A., Dutz, J. P., Vender, R. B., Gniadecki, R., Cooper, C., Gisondi, P., Gooderham, M., Hong, C. H., Kirchhof, M. G., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17075 · Cited by 7
Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice
Paschall, A. V., Ozdilek, A., Briner, S. L., Brindley, M. A., & Avci, F. Y. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.058 · Cited by 7
The shifting roles and toxicities of cellular therapies in B‐cell malignancies
Makos, O. L., & D'Angelo, C. R. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14145 · Cited by 7
Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus
Eichenfield, L. F., Boguniewicz, M., Lauren, C. T., Leung, D. Y. M., Levy, M. L., Schneider, L. C., Siegfried, E. C., Tom, W. L., & Paller, A. S. (2024) · Dermatology · doi:10.1159/000540920 · Cited by 9
“Based on studies of other diseases, systemic therapies, including methotrexate, SCSs, and JAK inhibitors, may reduce protective antibody titers in adults following vaccination [77 – 84].”
Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population
Garde, J., Fernández-Murga, M. L., Giner‐Bosch, V., Domínguez-Márquez, V., Sánchez, J. G., Soler‐Cataluña, J. J., Chulía, F., Peris, B. H., Piera, N., & Llombart‐Cussac, A. (2020) · Cancers · doi:10.3390/cancers12123513 · Cited by 6
Approach to vaccination in systemic lupus erythematosus on biological treatment
Yıldırım, R., Oliveira, T., & Isenberg, D. A. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224071 · Cited by 6
“8 42–44 More encouragingly, a study by Arad et al reported that cellular immunity remained preserved in patients with RA treated with RTX. 45 Westra et al showed that an in- incremental increase in IgM and IgG (IgG1 and IgG3) antibodies against both influenza strains was inadequate in the RTX…”
Background
Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey ( Macaca fasicularis ): A summary of three pre-clinical immunotoxicology evaluations
Komocsar, W. J., Blackbourne, J. L., Halstead, C. A., Winstead, C. J., & Wierda, D. (2015) · Journal of Immunotoxicology · doi:10.3109/1547691x.2014.994793 · Cited by 6
A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany
Hasseli, R., Pfeil, A., Krause, A., Schulze‐Koops, H., Müller‐Ladner, U., Specker, C., for the COVID-19 Task Force of the German Society for Rheumatology (DGRh), Hoyer, B. F., Lorenz, H., Regierer, A. C., et al. (2021) · Rheumatology International · doi:10.1007/s00296-021-04986-1 · Cited by 6
Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis
Mohammadi, I., Firouzabadi, S. R., Aghajanian, S., Aarabi, A., Mohammadifard, F., Sadraei, S., Alinejadfard, M., Etemadifar, M., & Salari, M. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106668 · Cited by 5
Vaccination Update and Specific Concerns for RA
Urquiaga, M., Winthrop, K. L., & Curtis, J. R. (2025) · Current Rheumatology Reports · doi:10.1007/s11926-025-01197-6 · Cited by 6
Immunologic Response to SARS-CoV-2 Vaccination in Pediatric Kidney Transplant Recipients: A Systematic Review and Meta-Analysis
Emmanouilidou-Fotoulaki, E., Karava, V., Dotis, J., Kondou, A., & Printza, N. (2023) · Vaccines · doi:10.3390/vaccines11061080 · Cited by 5
Maternal and neonatal antibody levels on pertussis vaccination in pregnant women on immune-modulating therapy for rheumatic disease
Ghalandari, N., Immink, M. M., Röder, E., Bruijning-Verhagen, P. C. J. L., Smeele, H. T. W., Crijns, H. J. M. J., van der Maas, N., Bekker, M. N., Sanders, E. A. M., & Dolhain, R. J. E. M. (2023) · RMD Open · doi:10.1136/rmdopen-2023-002985 · Cited by 5
Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments
Liao, H., Tung, H.-Y., Chou, C.-T., Hc, T., Yen, Y.-N., & Tsai, C. (2022) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2022.2062822 · Cited by 5
Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine
Dudley, H. M., O'Mara, M., Auma, A. W. N., Gong, J. D., Ross, Y., Gurevich, N., Carbone, S., Reihs, A., Nguyen, Y., McComsey, G. A., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.033 · Cited by 6
Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024
Rivera‐Izquierdo, M., Morales-Portillo, A., de Alba, I. G.-F., Fernández‐Martínez, N. F., Schoenenberger-Arnaiz, J. A., Quintana, J. L. B., & Valero-Ubierna, C. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2401839 · Cited by 5
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
Prelog, M. (2013) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.s6-007 · Cited by 5
The Problem of Lower Respiratory Tract Infections in Rheumatology: Relevance and Ways of Solution
Belov, B. S., Bukhanova, D. V., Тарасова, Г. М., & Muravyova, N. V. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-6-58-66 · Cited by 5
Should we vaccinate during an active rheumatic disease?
Bijl, M., Westra, J., Mancuso, S., Bearzi, P., Giacomelli, R., & Conti, F. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103426 · Cited by 5
Self-citation
Vaccination of immunocompromised hosts
Ljungman, P. T. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00016-1 · Cited by 5
Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al
Friedman, M., & Winthrop, K. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220398 · Cited by 5
Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus
Boguniewicz, M., Levy, M. L., Eichenfield, L. F., Lauren, C. T., Leung, D. Y. M., Schneider, L. C., Siegfried, E. C., Tom, W. L., & Paller, A. S. (2024) · The Journal of Pediatrics Clinical Practice · doi:10.1016/j.jpedcp.2024.200121 · Cited by 4
Immunisation against vaccine-preventable diseases in individuals receiving immunosuppressive targeted therapies
Wang, X., Patel, C., Sharma, K., Giles, M., Burns, P. L., Macartney, K. K., Flanagan, K. L., Teh, B. W., & Williams, P. C. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128399 · Cited by 4
Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How
van Beers, J. J. B. C., & Damoiseaux, J. G. M. C. (2021) · Biomolecules · doi:10.3390/biom11010116 · Cited by 4
“, at least six months after rituximab) a sufficient vaccination response can still be achieved [84], but this is obviously dependent on confirmation of the expected recovery of the B-cell compartment.”
Background
The Hong Kong Society of Rheumatology Consensus Recommendations for COVID-19 Vaccination in Adult Patients with Autoimmune Rheumatic Diseases
So, H., Mok, C. C., & Yip, R. M.-L. (2021) · Journal of Clinical Rheumatology and Immunology · doi:10.1142/s2661341721400010 · Cited by 4
Expert Panel Consensus Statements on Vaccination for Adults with AIRD in India
Jain, V. K., Mohanasundaram, K., Kumar, S., Kavadichanda, C. G., Irlapati, R. V., Mishra, N., Veeraraghavan, B., Swaminathan, S., Lakshminarayanan, D., Baghel, S., et al. (2024) · Indian Journal of Rheumatology · doi:10.1177/09733698241272078 · Cited by 4
Mitigating infection risk with immunotherapy for rheumatoid arthritis
Subesinghe, S., Whittaker, M., & Galloway, J. B. (2015) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.15.18 · Cited by 4
Dexamethasone Release from Glutaraldehyde Cross-Linked Chitosan Microspheres: In Vitro/In Vivo Studies and Non-Clinical Parameters Response in Rat Arthritic Model
Dhanaraju, M. D., Elizabeth, S., & Ganesan, P. (2011) · Journal of Pharmaceutical Investigation · doi:10.4333/kps.2011.41.5.279 · Cited by 4
Vaccination in rheumatology (the 2019 update of EULAR recommendations)
Belov, B. S., Тарасова, Г. М., & Muravyevа, N. V. (2019) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2019-618-625 · Cited by 4
“Данная вакцина была иммуногенной у больных РА, СКВ, ААВ, ССД и ПсА при лечении противовоспалительными препаратами всех классов, исключая ритуксимаб (РТМ) [23, 24].”
Severe COVID pneumonia and undetectable B cells after vaccination in patients previously treated with rituximab: a case series
Sakano, T., Bittner, E. A., & Chang, M. G. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2037359 · Cited by 4
Machine learning analysis of humoral and cellular responses to SARS-CoV-2 infection in young adults
Marcinkevičs, R., Silva, P. N., Hankele, A., Dörnte, C., Kadelka, S., Csik, K., Godbersen, S., Goga, A., Hasenöhrl, L., Hirschi, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1158905 · Cited by 4
“While B cells are critical for preventing infection or reducing inoculum size, T cell responses play a prominent role in clearing the infection (3, 4).”
Background
Vaccination of Immunocompromised Hosts
Ljungman, P. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00069-9 · Cited by 4
Papillomavirus humain et lupus érythémateux systémique
David, E., Bélot, A., Lega, J., Durieu, I., & Rousset‐Jablonski, C. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.12.009 · Cited by 4
A Review of the Efficacy of Influenza Vaccination in Autoimmune Disease Patients
Abdelahad, M., Ta, E., Kesselman, M. M., & Beckler, M. D. (2021) · Cureus · doi:10.7759/cureus.15016 · Cited by 4
“Patients with RA undergoing immunomodulatory treatments with biologic and non-biologic DMARDs are considered immunosuppressed, putting these patients at an increased risk for developing infections, especially involving the respiratory tract [23,28].”
BackgroundInfluential
Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort studyPreprint
Schiff, A. E., Wang, X., Patel, N. J., Kawano, Y., Kowalski, E. N., Cook, C., Vanni, K. M. M., Qian, G., Bade, K. J., Saavedra, A. A., et al. (2023) · medRxiv · doi:10.1101/2023.10.08.23296717 · Cited by 4
Influenza Vaccine Type-Dependent Antibody Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
Rasmussen, S. L., Kumar, P., Trebbien, R., Leutscher, P. D. C., & Rasmussen, C. (2023) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2023.23053 · Cited by 3
How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies
Rejeski, K., Banerjee, R. K., & Hill, J. A. (2026) · Blood · doi:10.1182/blood.2025032298 · Cited by 3
Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?
Suntornlohanakul, R., & Yeh, E. A. (2024) · Pediatric Drugs · doi:10.1007/s40272-024-00675-1 · Cited by 3
Multiple sclerosis, B cell therapy, and the COVID-19 vaccine
Seachrist, E. (2021) · eNeurologicalSci · doi:10.1016/j.ensci.2021.100319 · Cited by 3
Vaccinations in Children and Adolescents Treated With Immune-Modifying Biologics: Update and Current Developments
Martire, B., Ottaviano, G., Sangerardi, M., Sgrulletti, M., Chini, L., Dellepiane, R. M., Montin, D., Rizzo, C., Pignata, C., Marseglia, G. L., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.01.007 · Cited by 3
Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy
Mohamed, K. M., Álvarez-Hernández, M. P., García, C. J., Guevara‐Hoyer, K., Freites, D., Prada, C. M., Pérez-Sancristóbal, I., Fernández‐Gutiérrez, B., Chaín, G. M., Rodero, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092418 · Cited by 3
Vaccinations des patients adultes atteints d’une maladie rénale
Trivin, C., & Thervet, É. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.11.007 · Cited by 3
“13 [18] van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, 14 et al.”
Background
Vacunación en pacientes con enfermedades reumatológicas
Silveira, L. F., & González-Tomé, M. I. (2013) · Anales de Pediatría Continuada · doi:10.1016/s1696-2818(13)70122-7 · Cited by 3
Vaccine Use in Immunocompromised Adults
Whitaker, J. A., Valles, K. A., Tosh, P. K., & Poland, G. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00009-4 · Cited by 3
71 – Treatment of Rheumatoid Arthritis
O'Dell, J. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00071-2
Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
Watad, ‬., Soriano, A., & Shoenfeld, Y. (2015) · doi:10.1002/9781118663721.ch12 · Cited by 3
Vaccinoprophylaxis of infections and activity of immuno-inflammatory rheumatic diseases: pro et contra
Belov, B. S., & Muravyevа, N. V. (2024) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2024-69-1-2-65-73 · Cited by 2
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in patients with rheumatological diseases
Caponcello, M. G., Olivares-Navarro, P., Bonazzetti, C., Campoli, C., Savoldi, A., Gentilotti, E., Monforte, A. D., Caputo, S. L., Varela, L. O., Castrejón, I., et al. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.02.030 · Cited by 2
Vaccination for Patients with Rheumatic Diseases in the Era of Biologics
Han, S. H. (2018) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2018.25.2.100 · Cited by 2
COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers
Messmer, M., & Wagner‐Johnston, N. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1941939 · Cited by 2
“This impaired response lasts at least 6 months, with some studies demonstrating ongoing effect at 7–9 months [10].”
Background
Modern approaches to immunization of patients of rheumatologic profile
Belov, B. S., Тарасова, Г. М., & Muravyevа, N. V. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.05.200794 · Cited by 2
The Observation of Humoral Responses after Influenza Vaccination in Patients with Rheumatoid Arthritis Treated with Japanese Oriental (Kampo) Medicine: An Observational Study
Kogure, T., Harada, N., Oku, Y., Tatsumi, T., & Niizawa, A. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/320542 · Cited by 2
Biologika und Infekte in der Rheumatologie
Hügle, T., Daikeler, T. D., & Tyndall, A. (2014) · Therapeutische Umschau · doi:10.1024/0040-5930/a000480 · Cited by 2
“auf Influenza [9] und Pneumokokken [10] beeinträch-”
Impfungen unter immunsuppressiver Therapie chronisch entzündlicher Erkrankungen
Weisser, M. (2010) · Der Internist · doi:10.1007/s00108-010-2680-8 · Cited by 2
Vaccination antigrippale chez les patients atteints de maladies systémiques inflammatoires et/ou auto-immunes
Duchet-Niedziolka, P., Hanslik, T., Mouthon, L., Guillevin, L., & Launay, O. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2010.12.003 · Cited by 2
Clinical immunology – Autoimmunity in the Netherlands
Tervaert, J. W. C., & Kallenberg, C. G. M. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.10.008 · Cited by 2
Self-citation
Influenza vaccination in patients with multiple sclerosis is possible with some considerations.
Baghbanian, S. M. (2016) · Europe PMC (PubMed Central) · Cited by 2
COVID-19 in patients with glomerular disease
Turner‐Stokes, T., Edwards, H., & Lightstone, L. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000769 · Cited by 2
“Rituximab treatment has also been associated with a poorer response to the influenza vaccine [68].”
Background
The Practice Guideline for Vaccinating Korean Patients With Autoimmune Inflammatory Rheumatic Disease
Seo, Y. B., Moon, S., Jeon, C. H., Song, J. Y., Sung, Y., Jeong, S. J., Kwon, K. T., Kim, E. S., Kim, J., Kim, H., et al. (2020) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2020.27.3.182 · Cited by 2
Vaccinology Education of Nurses and the Current Immunoprophylaxis Recommendations for Children with Juvenile Idiopathic Arthritis
Bednarek, A., & Klepacz, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113736 · Cited by 2
“When these vaccines were administered 6–10 months after rituximab treatment, the responses ranged from sufficient [26,29] to weakened [30].”
Background
Vaccination against SARS-COV‑2 in oncology
Polyakov, A. A., Lunin, V. V., Abbaysbeyli, F. M., Тимофеева, О. Л., Ларионова, В. Б., Zeynalova, P. A., & Феденко, А. А. (2021) · Oncohematology · doi:10.17650/1818-8346-2021-16-2-70-80 · Cited by 2
A Lower Level of Post-Vaccinal Antibody Titer against Influenza Virus A H1N1 May Protect Patients with Autoimmune Rheumatic Diseases from Respiratory Viral Infections
Milanović, M., Kadijevich, D. M., Stojanovich, L., Milovanović, B., & Djoković, A. (2022) · Medicina · doi:10.3390/medicina58010076 · Cited by 2
Responses to vaccinations vary after rituximab therapy
Nassabeh, N. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.7 · Cited by 1
Composition of peripheral blood immune cell compartment in stage 5 chronic kidney disease is affected by smoking and other risk factors associated with systemic inflammatory response
Zahrádka, I., Tichánek, F., Majercikova, L., Dušková, J., Streitz, M., Schlickeiser, S., Osickova, K., Petr, V., Hrubá, P., Reinke, P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1608206 · Cited by 2
Impfungen bei Immunsuppression, Immundefekten und immunmodulierenden Therapien: Empfehlungen – Update 2026
Wiedermann, U., Wagner, A., Bartuschka, A., Berghoff, A. S., Donschacher, A., Eser, A., Förster‐Waldl, E., Göschl, L., Grabmeier‐Pfistershammer, K., Keil, F., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02754-4 · Cited by 2
Varicella zoster virus reinfection in a patient with refractory nephrotic syndrome: a case report
Kamei, K., Kaneda, T., Nishi, K., & Ogura, M. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07559-1 · Cited by 1
Consensus on the use of Rituximab in Rheumatoid Arthritis. A document with evidence based recommendations
Mola, E. M., Hernández, B., García‐Arias, M., Álvaro‐Gracia, J. M., Balsa, A., Gómez-Reino, J. J., de la Fuente, J. L. M., Martínez-Taboada, V. M., Ivorra, J. A. R., & Sanmartí, R. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/s2173-5743(11)70006-5 · Cited by 1
Impfungen vor Reisen bei Patienten mit rheumatischen Erkrankungen
Ehrenstein, B. P. (2011) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-010-0721-2 · Cited by 1
Infections Related to Biologic Modifier Therapy
Davies, H. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00107-9 · Cited by 1
Juvenile idiopathische Arthritis
Minden, K., Frosch, M., Roth, J., Holzinger, D., Ganser, G., Dannecker, G. E., Föll, D., Girschick, H. J., Huemer, C., Heiligenhaus, A., et al. (2013) · Springer eBooks · doi:10.1007/978-3-642-34728-3_4 · Cited by 1
Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy
Bilge, N., Can, F. K., & Yevgi, R. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-02125-6 · Cited by 1
Vaccination of Immunocompromised Hosts
Ljungman, P. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00070-0 · Cited by 1

Authors: van Assen, S., Holvast, A., Benne, C. A., Posthumus, M. D., van Leeuwen, M. A., Voskuyl, A. E., Blom, M., Risselada, A. P., de Haan, A., Westra, J., Kallenberg, C. G. M., & Bijl, M.
Affiliations: University Medical Center Groningen (NL)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Radboud University Nijmegen (NL)
University Medical Center Utrecht (NL)
ORCID: Voskuyl, Alexandre E.
Westra, Johanna
Venue: Arthritis & Rheumatism
Publisher: Wiley
Published: 2009-12-28
Volume: 62
Issue: 1
Pages: 75-81
ISSN: 0004-3591 (ISSN-L)
1529-0131
DOI: 10.1002/art.25033
OpenAlex: W2059903231
Cited by: 371
References: 18
Citations by year: 2026: 11 · 2025: 9 · 2024: 21 · 2023: 20 · 2022: 35 · 2021: 57 · 2020: 30 · 2019: 11 · 2018: 17 · 2017: 14 · 2016: 14 · 2015: 20 · 2014: 23 · 2013: 24 · 2012: 15
FWCI: 15.33
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Arthritis & Rheumatism (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: rheumatoid arthritis, rituximab, influenza vaccination, humoral immune response, influenza antibodies, seroprotection, seroconversion, methotrexate, CD19+ B cells, vaccine efficacy, disease activity, trivalent influenza vaccine, B-cell depletion, hemagglutination inhibition test, DAS28
MeSH terms: Rituximab, Antibodies, Monoclonal, Antibodies, Viral, Arthritis, Rheumatoid, Drug Therapy, Combination, Female, Hemagglutination Inhibition Tests, Humans, Immunization Schedule, Immunologic Memory, Influenza Vaccines, Male, Methotrexate, Middle Aged, Vaccines, Inactivated, B-Lymphocyte Subsets, Antirheumatic Agents, Antigens, CD20, Immunity, Humoral, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks